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Abstract 
Background: Control of vivax malaria in endemic areas requires management of recurrence. The Brazilian National 
Malaria Surveillance System (SIVEP-Malária) records every case of malaria in Brazil, but is not designed to differentiate 
between primary and recurrent infections. The aim of this study was to explore whether the information provided by 
SIVEP-Malária could be used to identify Plasmodium vivax recurrences, its risk factors and evaluate the effectiveness of 
short course primaquine (7–9 days: total dose 3–4.2 mg/kg) in preventing relapses.
Methods: In this observational retrospective cohort study, data matching of SIVEP-Malária records was undertaken 
using bloom filters to identify potential recurrences defined as microscopically-confirmed P. vivax episodes from the 
same individual occurring within a year. Generalized Estimation Equation (GEE) models were used to determine pre-
dictors of recurrence. Extended Cox-based conditional Prentice–Williams–Peterson models (PWP) models were used 
to evaluate time to recurrence.
Results: Between June 1, 2014 and May 31, 2015, 26,295 episodes fulfilled the criteria of potential recurrence among 
154,970 reported malaria episodes. Age ≤ 3 years, being male, literate, not-indigenous and having domestic working 
activities were identified as risk factors for recurrence. There was no difference in time to recurrence or recurrence 
frequency between patients treated with 14-day or 7–9 day primaquine regimens (HR = 1.02, 0.96–1.09) and RR = 0.97 
(0.90–1.04), respectively. The use of chloroquine alone was associated with a 1.43 (1.29–1.58, p < 0.0001) increased 
risk of P. vivax recurrence compared to patients who used chloroquine combined with short-course primaquine, the 
Brazilian standard of care. This was RR = 2.06 (1.48–2.86, p < 0.0001), RR = 1.90 (1.60–2.25, p = 0.0001) and RR = 1.14 
(1.00–1.29, p = 0.05) for recurrences occurring between 3–28, 29–60 and > 60 days, respectively. PWP models showed 
that the time to recurrence was longer in recipients of both primaquine and artemisinin-based combination therapy 
(ACT) compared to patients treated with chloroquine alone or with concomitant primaquine, HR = 2.2 (1.62–2.99, 
p < 0.0001), HR = 1.27 (0.97–1.66, p = 0.08), respectively.
Conclusion: Short course primaquine was as effective as 14-day regimens and associated with a halving of the risk 
and delay in time to recurrence of P. vivax infections in comparison to chloroquine alone. The study demonstrates the 
feasibility of using record linkage on routine surveillance data to identify potential P. vivax recurrences, associated risk 
factors and impact of treatment.
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Background
Malaria control was first implemented in Brazil in 1905. 
Initial success led to the eradication campaign in 1965 
[1], which lasted until the late 60s. The lowest number 
of annual cases, 36,900, was recorded in 1961 [2]. Dur-
ing the 90s, partly because of a growing population in the 
Amazon Region, over half a million cases per year were 
recorded, peaking in 1999 with 637,470 cases [3]. Since 
then, following the introduction of renewed malaria con-
trol efforts, including vector control and early diagnos-
tics and treatment with artemisinin-based combination 
therapy (ACT) [4, 5], a drop in malaria cases has been 
observed with a nadir of 143,552 malaria cases in 2014. 
Plasmodium vivax infections accounted for 84% of all 
cases, highlighting the growing importance of this specie.
Brazil is currently focusing on the elimination of both 
Plasmodium falciparum and P. vivax [6, 7]. Understand-
ing P. vivax recurrences is critical for malaria control in 
endemic areas. In Brazil, cases of malaria are recorded 
in the National System of Malaria Surveillance (SIVEP 
Malária). Although it is believed that over 99% of cases 
are recorded in this system, it is not designed to differ-
entiate between primary and recurrent malaria episodes. 
This study aimed to explore if and how routinely col-
lected data from the Health Surveillance System can be 
used to describe epidemiological patterns such as the 
event rate, the time interval between repeated episodes 
of vivax malaria, and risk factors of P. vivax recurrence, 
such as age or P. falciparum triggering a P. vivax episode.
The study also investigated the effectiveness of a 
7–9 days primaquine and its comparison with a 14 days 
primaquine regimen, the synergic effects of concomitant 
use of primaquine with chloroquine and the influence of 
the use of ACT on the time to P. vivax recurrence.
Methods
National malaria treatment guidelines Brazil
The current first-line treatment for vivax infection is 
3 days of chloroquine (600 mg on day 1, and 450 mg on 
days 2 and 3) with concomitant use of a short course of 
primaquine (7–9 days: total dose 3–4.2 mg/kg). The pre-
scription of 14-day regimens of primaquine is indicated 
only if the health care provider can monitor the adher-
ence. Pregnant women standardly receive the 3-day 
treatment course of chloroquine but do not receive pri-
maquine. Only if they experience more than one episode 
of clinical malaria during a single pregnancy, they receive 
weekly chloroquine chemoprophylaxis for 12  weeks or 
until delivery. The current first-line treatment for uncom-
plicated falciparum malaria is artemether-lumefantrine 
[8] combined with a single dose of primaquine (maxi-
mum total dose 45 mg).
Population and study design
This observational retrospective cohort study used 
records of the National System of Malaria Surveillance 
(SIVEP Malária) from nine States in the Brazilian Legal 
Amazon Region between 1st June 2014 and 31st May 
2015 inclusive. The SIVEP Malaria is an online surveil-
lance system from the Ministry of Health that records all 
notified cases of malaria in Brazil since 2003 [9]. This sur-
veillance system was designed to identify outbreaks and 
track the effectiveness of malaria control.
It is estimated that 99.6% of malaria cases notified in 
Brazil were captured by the system in 2014 [5]. High rates 
of notification are driven by the compulsory notification 
of malaria in Brazil and because notification is neces-
sary to access free malaria treatment, which is provided 
exclusively by the National Health System (Sistema Único 
de Saúde-SUS) [9] for each microscopy or rapid diagnos-
tic tests (RDT) confirmed case of malaria. Only malaria 
cases in specific populations, such as illegal gold miners 
working in border areas, may be under represented in the 
National System of Malaria Surveillance.
Recurrences and data matching
National guidelines state that any malaria positive smears 
conducted within 60 days of previous P. vivax infections 
and within 40 days for P. falciparum should be recorded 
as ‘follow up’ smears [8]. This information relies upon 
the reports provided by the patient to the health worker 
because the SIVEP Malaria system does not include a 
unique individual patient identifier, making it difficult to 
easily identify recurrent events.
Bloom filters matching strategies [10] were used to link 
records of different clinic visits made by the same patient 
to determine the interval in days between visits. A filter 
of 240 bites was defined, using a combination of patient’s 
name (A), patient’s mother’s name (B), date of birth 
(C), and municipality of residency (D) (Venn diagram 
presented in Additional file  1). Absent identifiers were 
replaced with random values to avoid unwanted simi-
larity. The degree of similarity between two filters was 
assessed using the Dice Coefficient calculated on the two 
binary vectors [11]. The score was scaled to a maximum 
of 10,000. Different combinations of identifiers were used 
in separate reduplication runs: (a) ABCD, (b) ABD and 
(c) ABC. These were then individually inspected to see 
whether the pairs were coherent. This procedure allowed 
the exclusion of false matches.
Evaluation of the population and recurrences
Baseline characteristics available from the SIVEP form 
(see Additional file  2) were evaluated. Age catego-
ries were matched to the primaquine dose bands of the 
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Brazilian treatment guidelines. A map of the incidence 
rate of vivax recurrences (cases per 1000) at the local 
governmental level of the Federative Republic of Bra-
zil (municipalities) was obtained using Tableau Desktop 
(version 10.3).
The effect of baseline variables on recurrent events was 
expressed as relative risks (RR) obtained from log-bino-
mial regression models with random effect for patients 
using Generalized Estimation Equation (GEE). Time 
between recurrent events was stratified as 3–28, 29–60 
and > 60  days based on the chloroquine half-life and 
per national definitions of recurrence. The same model 
was used to estimate the synergic effect of the concom-
itant use of primaquine and chloroquine on P. vivax 
recurrence.
Extended Cox-based conditional Prentice–Williams–
Peterson (PWP) survival models for repeated ordered 
events were used for the analysis of time to vivax recur-
rence [12]. The time interval between sequential malaria 
episodes were graphically displayed using Kaplan–Meier 
curves and results presented as median (95% CI) time to 
recurrence. Two-sided p-values were used and statistical 
significance defined as < 0.05. Analysis was conducted 
using R (version 3.2.5) and IBM SPSS statistics (version 
24.0).
Ethics statement
The study protocol was reviewed and approved by the 
Ethics Committee at National Institute of Infectious Dis-
ease, Oswaldo Cruz Foundation (No. 1.591.434 CAAE 
56245716.1.0000.5262) and complied with procedures 
of the Health Surveillance Secretary (SVS)—Ministry of 
Health of Brazil to access datasets containing personal 
information. The investigators ensured confidentiality of 
all records. The study is registered at the Brazilian Regis-
ter of Clinical Trials (RBR-3n947j), a primary repository 
of WHO.
Results
Data matching results
Between June 1, 2014 and May 31, 2015 inclusive, 26,295 
recurrences involving 18,185 patients were identi-
fied among 154,970 reported malaria episodes involv-
ing 128,675 patients using the Bloom Filter matching 
strategy. The strategy selected had ABCD, ABD and 
ABC Dice threshold scores of 9500. Individual record 
inspection identified 241 out of 17,983 matches as false 
matches. Some of these involved multiple potential 
matches between episodes from multiple patients (i.e. 
one visit matching to more than one patient). These 241 
potential false matches were manually inspected and cor-
rected, which resulted in 493 additional matches.
The original SIVEP Malaria dataset had 28,062 recur-
rent malaria episodes, however 1767 episodes were 
recurrences occurring within 2  days from the initial 
report and were excluded from the analysis giving a total 
of 26,295 recurrences that were used in the model (Addi-
tional file 3). The baseline characteristics are presented in 
Table 1.
Plasmodium vivax malaria recurrence
The final combination of parameters of the strategy 
selected resulted in more matches than the number of 
recurrences reported by the health agents. The incidence 
rates of P. vivax recurrence varied considerably at the 
municipality level, reflecting the widespread area over 
which malaria transmission occurs in Brazil [13] (Fig. 1).
Risk factors for Plasmodium vivax recurrences
Among those who took primaquine, the risk of recur-
rence decreased with increasing age. Compared to 
children aged ≤ 3  years, children aged 4–8  years and 
older adults had a 20% and 38% lower risk (4–8  years: 
RR = 0.80, 95% CI 0.75–0.86, p < 0.0001; adults RR = 0.62, 
0.57–0.67, p < 0.0001, respectively). Being male increased 
the risk of P. vivax recurrence (RR = 1.11, 1.07–1.14, 
p < 0.0001). The native indigenous population were at 
lower risk compared to other groups. The risk of vivax 
recurrence was higher in all education levels compared to 
those who were illiterate. Individual with domestic work-
ing activities were at the highest risk of recurrence com-
pared to other occupations.
Similar risk factors were identified for time to recur-
rence. This reduced with each successive episode of P. 
vivax malaria (Table  2 and Fig.  2). Other factors asso-
ciated with shorter time to recurrence included age 
≤ 3  years, male gender, no hypnozoite treatment, and 
domestic occupation (Table  3). Previous P. falciparum 
infection was not associated with a shorter time to recur-
rence HR = 1.04, 0.93; 1.16, p = 0.50.
Effectiveness of 7 days versus 14 days primaquine on P. 
vivax recurrence incidence
Overall, 6226 (4.9%) patients were prescribed a 14-day 
course of primaquine and 120,608 (95.1%) a 7-day course 
(total dose 3–4.2  mg/kg). All received 3-days of chloro-
quine for P. vivax malaria. The risk of P. vivax recurrence 
was similar between the two regimens: 14-day: 887/6226 
(14.3%) vs 7–9  day: 17,610/12,0608 (14.6%), RR = 0.97 
(0.90–1.04), p = 0.96. Similar conclusions could be drawn 
from the PWP survival model which also showed no dif-
ference in the time to recurrence (HR = 1.02, 0.96–1.09, 
p = 0.52).
Page 4 of 10Daher et al. Malar J           (2019) 18:18 
Ta
bl
e 
1 
Po
pu
la
ti
on
 b
as
el
in
e 
ch
ar
ac
te
ri
st
ic
s 
of
 th
e 
st
ud
y 
po
pu
la
ti
on
Va
ri
ab
le
s
Ca
te
go
ri
es
Pa
tie
nt
s
n 
= 1
28
,6
75
 
(%
)
M
al
ar
ia
 c
as
es
n 
= 1
53
,2
03
 (%
)
Re
su
lts
 p
er
 s
pe
ci
e
Pa
ra
si
ta
em
ia
Vi
va
x
Fa
lc
ip
ar
um
M
ix
ed
 F
 + 
V
M
al
ar
ia
e
N
on
 
fa
lc
ip
ar
um
Le
ss
 th
an
 h
al
f 
cr
os
s
H
al
f t
o 
on
e 
cr
os
s
Tw
o 
cr
os
se
s
Th
re
e–
fo
ur
 
cr
os
se
s
A
ge
≤ 
3 
ye
ar
s
72
31
 (5
.6
2)
85
84
 (5
.6
)
69
0 
(0
.4
5)
34
 (0
.0
2)
0 
(0
)
77
 (0
.0
5)
19
00
 (1
.2
4)
27
91
 (1
.8
2)
40
82
 (2
.6
7)
50
7 
(0
.3
3)
4–
8 
ye
ar
s
98
84
 (7
.6
8)
10
,8
37
 (7
.0
7)
10
60
 (0
.6
9)
54
 (0
.0
4)
1 
(0
)
69
 (0
.0
5)
30
39
 (1
.9
8)
37
99
 (2
.4
8)
46
86
 (3
.0
6)
40
6 
(0
.2
7)
9–
11
 y
ea
rs
63
44
 (4
.9
3)
69
30
 (4
.5
2)
67
6 
(0
.4
4)
26
 (0
.0
2)
1 
(0
)
41
 (0
.0
3)
21
92
 (1
.4
3)
24
77
 (1
.6
2)
27
85
 (1
.8
2)
16
6 
(0
.1
1)
12
–1
4 
ye
ar
s
70
36
 (5
.4
7)
76
37
 (4
.9
8)
68
0 
(0
.4
4)
42
 (0
.0
3)
0 
(0
)
32
 (0
.0
2)
22
60
 (1
.4
8)
28
66
 (1
.8
7)
30
65
 (2
)
15
6 
(0
.1
)
15
–3
5 
ye
ar
s
39
,7
04
 (3
0.
86
)
41
,9
28
 (2
7.
37
)
44
67
 (2
.9
2)
33
3 
(0
.2
2)
16
 (0
.0
1)
15
2 
(0
.1
)
12
,3
28
 (8
.0
5)
14
,7
54
 (9
.6
4)
18
,4
12
 (1
2.
02
)
11
67
 (0
.7
6)
O
ld
er
 th
an
 
36
 y
ea
rs
58
,4
76
 (4
5.
44
)
57
,0
99
 (3
7.
27
)
11
,2
84
 (7
.3
7)
37
0 
(0
.2
4)
18
 (0
.0
1)
65
 (0
.0
4)
24
,5
65
 (1
6.
04
)
24
,8
78
 (1
6.
25
)
18
,1
98
 (1
1.
88
)
10
69
 (0
.7
)
G
en
de
r
Fe
m
al
e
51
,3
27
 (3
9.
89
)
52
,8
61
 (3
4.
5)
76
58
 (5
)
31
3 
(0
.2
)
5 
(0
)
19
7 
(0
.1
3)
19
,4
69
 (1
2.
71
)
20
,9
56
 (1
3.
69
)
19
,0
37
 (1
2.
43
)
12
82
 (0
.8
4)
M
al
e
77
,3
46
 (6
0.
11
)
80
,1
53
 (5
2.
32
)
11
,1
98
 (7
.3
1)
54
6 
(0
.3
6)
31
 (0
.0
2)
23
9 
(0
.1
6)
26
,8
14
 (1
7.
51
)
30
,6
08
 (1
9.
99
)
32
,1
91
 (2
1.
02
)
21
89
 (1
.4
3)
Ra
ce
W
hi
te
88
25
 (6
.9
7)
91
98
 (6
)
11
82
 (0
.7
7)
59
 (0
.0
4)
0 
(0
)
21
 (0
.0
1)
28
93
 (1
.8
9)
32
03
 (2
.0
9)
40
22
 (2
.6
3)
31
1 
(0
.2
)
A
fri
ca
n 
ba
ck
-
gr
ou
nd
50
24
 (3
.9
7)
49
83
 (3
.2
5)
87
2 
(0
.5
7)
46
 (0
.0
3)
3 
(0
)
11
 (0
.0
1)
15
48
 (1
.0
1)
17
68
 (1
.1
5)
24
00
 (1
.5
7)
18
4 
(0
.1
2)
A
si
an
 b
ac
k-
gr
ou
nd
13
10
 (1
.0
3)
13
56
 (0
.8
9)
16
1 
(0
.1
1)
14
 (0
.0
1)
0 
(0
)
2 
(0
)
36
9 
(0
.2
4)
44
1 
(0
.2
9)
65
6 
(0
.4
3)
64
 (0
.0
4)
M
ix
ed
 b
ac
k-
gr
ou
nd
88
,9
27
 (7
0.
25
)
91
,7
56
 (5
9.
89
)
14
,3
44
 (9
.3
6)
60
8 
(0
.4
)
23
 (0
.0
2)
16
2 
(0
.1
1)
34
,9
02
 (2
2.
79
)
34
,3
55
 (2
2.
44
)
35
,0
81
 (2
2.
91
)
22
30
 (1
.4
6)
N
at
iv
e 
in
di
g-
en
ou
s
22
,4
92
 (1
7.
77
)
23
,1
39
 (1
5.
1)
22
50
 (1
.4
7)
12
9 
(0
.0
8)
8 
(0
.0
1)
24
0 
(0
.1
6)
61
19
 (4
)
11
,0
17
 (7
.1
9)
77
66
 (5
.0
7)
58
3 
(0
.3
8)
N
ot
 in
fo
rm
ed
14
,5
94
 (1
1.
34
)
25
83
 (1
.6
9)
48
 (0
.0
3)
3 
(0
)
2 
(0
)
0 
(0
)
45
3 
(0
.3
)
78
1 
(0
.5
1)
13
03
 (0
.8
5)
99
 (0
.0
6)
Ye
ar
s 
in
 S
ch
oo
l
Ill
ite
ra
te
77
,1
41
 (5
9.
95
)
14
,5
23
 (9
.4
8)
21
99
 (1
.4
4)
94
 (0
.0
6)
3 
(0
)
80
 (0
.0
5)
57
21
 (3
.7
4)
56
94
 (3
.7
2)
50
33
 (3
.2
9)
34
7 
(0
.2
3)
In
co
m
pl
et
e/
co
m
pl
et
e 
fu
nd
am
en
ta
l 
st
ud
ie
s
20
,7
25
 (1
6.
11
)
78
,7
80
 (5
1.
42
)
11
,9
58
 (7
.8
1)
53
4 
(0
.3
5)
28
 (0
.0
2)
23
6 
(0
.1
5)
27
,9
19
 (1
8.
23
)
31
,4
15
 (2
0.
52
)
30
,0
06
 (1
9.
6)
18
26
 (1
.1
9)
In
co
m
pl
et
e/
co
m
pl
et
e 
hi
gh
 s
ch
oo
l
22
27
 (1
.7
3)
22
,6
37
 (1
4.
78
)
29
61
 (1
.9
3)
15
2 
(0
.1
)
5 
(0
)
23
 (0
.0
2)
78
92
 (5
.1
5)
84
28
 (5
.5
)
88
89
 (5
.8
1)
53
1 
(0
.3
5)
G
ra
du
at
io
n
13
,9
88
 (1
0.
87
)
11
80
 (0
.7
7)
15
7 
(0
.1
)
3 
(0
)
0 
(0
)
2 
(0
)
45
4 
(0
.3
)
44
4 
(0
.2
9)
41
3 
(0
.2
7)
29
 (0
.0
2)
N
ot
 in
fo
rm
ed
72
31
 (5
.6
2)
15
,8
95
 (1
0.
38
)
15
82
 (1
.0
3)
76
 (0
.0
5)
0 
(0
)
95
 (0
.0
6)
42
98
 (2
.8
1)
55
84
 (3
.6
5)
68
87
 (4
.5
)
73
8 
(0
.4
8)
Page 5 of 10Daher et al. Malar J           (2019) 18:18 
Ta
bl
e 
1 
(c
on
ti
nu
ed
)
Va
ri
ab
le
s
Ca
te
go
ri
es
Pa
tie
nt
s
n 
= 1
28
,6
75
 
(%
)
M
al
ar
ia
 c
as
es
n 
= 1
53
,2
03
 (%
)
Re
su
lts
 p
er
 s
pe
ci
e
Pa
ra
si
ta
em
ia
Vi
va
x
Fa
lc
ip
ar
um
M
ix
ed
 F
 + 
V
M
al
ar
ia
e
N
on
 
fa
lc
ip
ar
um
Le
ss
 th
an
 h
al
f 
cr
os
s
H
al
f t
o 
on
e 
cr
os
s
Tw
o 
cr
os
se
s
Th
re
e–
fo
ur
 
cr
os
se
s
Ec
on
om
ic
 
ac
tiv
ity
D
om
es
tic
12
,0
62
 (9
.3
7)
13
,0
56
 (8
.5
2)
15
95
 (1
.0
4)
77
 (0
.0
5)
0 
(0
)
27
 (0
.0
2)
43
53
 (2
.8
4)
49
91
 (3
.2
6)
50
93
 (3
.3
3)
27
5 
(0
.1
8)
O
th
er
s
75
,4
68
 (5
8.
65
)
78
,9
55
 (5
1.
54
)
10
,9
39
 (7
.1
4)
37
4 
(0
.2
4)
13
 (0
.0
1)
16
4 
(0
.1
1)
28
,3
06
 (1
8.
49
)
30
,0
73
 (1
9.
64
)
29
,6
99
 (1
9.
4)
20
92
 (1
.3
7)
A
gr
ic
ul
tu
re
 
liv
es
to
ck
28
,1
92
 (2
1.
91
)
28
,2
53
 (1
8.
44
)
43
93
 (2
.8
7)
18
6 
(0
.1
2)
4 
(0
)
15
3 
(0
.1
)
10
,2
13
 (6
.6
7)
12
,4
69
 (8
.1
4)
95
97
 (6
.2
7)
51
2 
(0
.3
3)
To
ur
is
m
27
59
 (2
.1
4)
28
83
 (1
.8
8)
28
7 
(0
.1
9)
18
 (0
.0
1)
2 
(0
)
8 
(0
.0
1)
64
9 
(0
.4
2)
11
03
 (0
.7
2)
13
26
 (0
.8
7)
11
0 
(0
.0
7)
M
in
in
g
59
99
 (4
.6
6)
57
22
 (3
.7
3)
11
25
 (0
.7
3)
17
2 
(0
.1
1)
10
 (0
.0
1)
23
 (0
.0
2)
14
86
 (0
.9
7)
13
34
 (0
.8
7)
38
12
 (2
.4
9)
36
8 
(0
.2
4)
Ve
ge
ta
l e
xt
ra
c-
tiv
is
m
10
48
 (0
.8
1)
95
5 
(0
.6
2)
20
8 
(0
.1
4)
18
 (0
.0
1)
7 
(0
)
3 
(0
)
29
3 
(0
.1
9)
35
4 
(0
.2
3)
50
8 
(0
.3
3)
31
 (0
.0
2)
Fi
sh
in
g 
hu
nt
in
g
27
58
 (2
.1
4)
27
58
 (1
.8
)
28
2 
(0
.1
8)
10
 (0
.0
1)
0 
(0
)
56
 (0
.0
4)
89
0 
(0
.5
8)
11
01
 (0
.7
2)
97
0 
(0
.6
3)
75
 (0
.0
5)
Ro
ad
 d
am
 c
on
-
st
ru
ct
io
n
38
9 
(0
.3
)
43
3 
(0
.2
8)
28
 (0
.0
2)
4 
(0
)
0 
(0
)
2 
(0
)
94
 (0
.0
6)
14
0 
(0
.0
9)
22
3 
(0
.1
5)
8 
(0
.0
1)
Page 6 of 10Daher et al. Malar J           (2019) 18:18 
Effectiveness of the concomitant use of primaquine on P. 
vivax recurrence incidence
As stated previously, primaquine treatment is not recom-
mended in Brazil for pregnant women and chloroquine 
chemoprophylaxis for pregnant women is only given 
after the second malaria episode. This enabled the use of 
the pregnant population with a single vivax recurrence as 
a comparator to assess the effect of hypnozoite treatment.
Pregnant patients who did not take short-course pri-
maquine had a 1.43 (95% CI [1.29–1.58]) risk of P. vivax 
recurrence compared to non-pregnant patients who took 
primaquine. This was RR = 2.06 (1.48–2.86, p < 0.0001), 
RR = 1.90 (1.60–2.25, p = 0.0001) and RR = 1.14 (1.00–
1.29, p = 0.05) for recurrences occurring between 3–28, 
28–60 and > 60  days. The time to a P. vivax recurrence 
was also shorter in pregnant women (HR = 1.53, 1.39–
1.69, p < 0.0001).
Overall, 399 patients received ACT with a primaquine 
total dose of 3–4.2 mg/kg starting after the third day of 
ACT to treat mixed P. vivax and P. falciparum infec-
tions. There was a reduced risk of P. vivax recurrence 
in those taking ACT and sequential primaquine com-
pared to pregnant patients treated with chloroquine only 
(RR = 0.70, 0.52–0.93, p = 0.015). Plasmodium vivax 
recurrence also took longer in patients taking ACT and 
sequential primaquine than chloroquine alone treated 
patients HR = 2.2 (1.62–2.99, p < 0.0001), and those 
treated with chloroquine and with concomitant pri-
maquine, HR = 1.27 (0.97–1.66, p = 0.08), but this differ-
ence was of borderline statistical significance.
Discussion
This study demonstrated the potential for the use of 
routinely collected public health surveillance records to 
evaluate the epidemiology and risk factors of recurrent 
P. vivax malaria in Brazil. The computational tools avail-
able allowed the processing and successful automated 
matching of over 150,000 case records to identify poten-
tial recurrent infections. This provided access to unique 
data that allowed us to identify associated risk factors 
and impact of treatment using routine surveillance data. 
The analysis showed that short 7–9  day courses of pri-
maquine with concomitant use of chloroquine was more 
effective than chloroquine alone, and equally as effective 
as the 14-day regimen in preventing P. vivax recurrences. 
ACT-primaquine combinations were also more effective 
Fig. 1 Incidence of Plasmodium vivax recurrence (cases per 1000)
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than chloroquine alone or chloroquine–primaquine 
combinations in delaying recurrence, although the latter 
was not statistically significant.
An important part of this analysis included matching 
of case records in the absence of a unique patient identi-
fier to link different episodes that occurred in the same 
individual during a 1-year period. Although there are 
limitations in the quality of the routine data in many sur-
veillance systems in resource poor settings, using com-
putational approaches to explore the large datasets may 
help generate evidence to support public health policies 
[14]. Bloom filters are designed to screen vast amounts 
of data with applications in many fields of computational 
science [15] and are aimed at detecting duplicate entries. 
The quality of data entry is a major factor in defining the 
best matching strategy and, therefore, there is no stand-
ard strategy suitable for all datasets. This meant that, 
depending on the completeness of the dataset using high 
Dice’s coefficients in the matching strategy led to a low 
number of matches (low sensitivity). However, the visual 
inspection of the lower thresholds had too many false 
matches (low specificity). The current strategy identified 
a greater frequency of recurrences than the one reported 
by the health agents based on patient’s recall.
Brazil recommends a short 7–9 days courses (total dose 
3–4.2  mg/kg). Fourteen days of primaquine is only rec-
ommended in Brazil either when patients are considered 
likely to be compliant or can undergo supervised treat-
ment. The similar effectiveness between these two regi-
mens is encouraging, reinforcing the idea that cure rate is 
a function of the total primaquine dose rather than treat-
ment length [16, 17].
The importance of addressing the effectiveness of pri-
maquine in real life for radical cure of P. vivax infections 
was highlighted recently [18]. This equal effectiveness of 
the short-course regimen has important practical impli-
cations because a patient friendly primaquine regimen 
is desirable and regimens of shorter duration are more 
likely to be adhered to [19]. The evidences on which 
this short-course primaquine regimen in Brazil is based 
Table 2 Median time to  sequential episodes of  vivax 
malaria
Recurrences Number of vivax 
recurrences
Median time (95% CI) 
to recurrence (days)
1st 17,460 71 (70.19–71.81)
2nd 4967 65 (63.83–66.17)
3rd 1429 60 (58.33–61.67)
4th 452 56 (52.08–59.92)
5th 150 54 (46.41–61.59)
6th 49 41 (31.47–50.53)
7th 15 38 (29.51–46.49)
8th 6 46 (34.24–57.76)
Overall 69 (68.37–69.63)
Fig. 2 Kaplan Meier graph sequential episodes of vivax malaria
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on are a limited number of clinical trials [20, 21], pro-
grammatic experience, and historical evidence suggest-
ing that the efficacy of primaquine is more a function of 
the cumulative dose than the duration of treatment [17]. 
However, the evidence has been deemed insufficient to 
support international guidelines. An ongoing systematic 
review [22] and the results of this current analysis may 
increase this body of evidence.
Children under 3  years old had an increased risk of 
recurrence compared to all other age categories, with a 
trend towards increasingly lower risk with increasing 
age. There are several potential explanations for this in 
addition to differences in acquired immunity: The doses 
of chloroquine and primaquine may be inadequate at this 
young age [23] or the absence of child-friendly formula-
tions may result in poor adherence and reduced effec-
tiveness. Herein it was demonstrated a reduced risk of 
recurrence in the native indigenous population. Similarly, 
it was also showed that the risk was lowest in the illiterate 
population. Both may reflect higher exposure rates early 
in life and a more rapid acquisition of protective immu-
nity in these groups [24].
Previous falciparum infection was not found to 
caused more rapid recurrence of P. vivax, in contrast to 
Table 3 Factors related to P. vivax recurrence
REF reference group
Predictor factor Categories Generalized Estimation Equation (GEE) model Prentice, Williams 
and Peterson (PWP) 
survival model
N (%)
N = 151,784
RR (95% CI), p value HR (95% CI), p value
Age categorical Older than 36 years 68,173 (44.9) 0.62 (0.57–0.67), p < 0.0001 0.75 (0.70; 0.81), p < 0.0001
15–35 years 46,380 (30.6) 0.71 (0.65–0.77), p < 0.0001 0.78 (0.72;0.84), p < 0.0001
12–14 years 8337 (5.5) 0.77 (0.7–0.85), p < 0.0001 0.81 (0.74;0.88), p < 0.0001
9–11 years 7604 (5) 0.82 (0.75–0.91), p < 0.0001 0.87 (0.80;0.96), p = 0.003
4–8 years 11,982 (7.9) 0.8 (0.75–0.86), p < 0.0001 0.83 (0.78;0.88), p < 0.0001
≤ 3 9308 (6.1) REF REF
Hypnozoite treatment No primaquine 2667 (1.8) 1.43 (1.29–1.58), p < 0.0001 1.53 (1.39;1.69), p < 0.0001
Primaquine 3–4.2 mg/kg 149,117 (98.2) REF REF
Gender Male 90,914 (59.9) 1.11 (1.07–1.14), p < 0.0001 1.08 (1.05;1.11), p < 0.0001
Female 60,870 (40.1) REF REF
Ethnic background Not informed 1377 (0.9) 1.60 (1.4–1.82), p < 0.0001 1.19 (1.02;1.38), p = 0.03
Native indigenous 25,705 (16.9) 0.78 (0.73–0.84), p < 0.0001 0.89 (0.84;0.95), p < 0.0001
Mixed background 106,819 (70.4) 1.03 (0.97–1.09), p = 0.34 0.95 (0.87;1.04), p = 0.25
Asian background 1527 (1) 0.96 (0.8–1.15), p = 0.68 0.94 (0.80;1.11), p = 0.49
African background 5908 (3.9) 0.94 (0.86–1.04), p = 0.23 0.95 (0.87;1.04), p = 0.25
White 10,448 (6.9) REF REF
Economic activity Road dam construction 467 (0.3) 1.01 (0.8–1.27), p = 0.94 0.92 (0.74;1.13), p = 0.42
Fishing hunting 3106 (2) 0.72 (0.63–0.82), p < 0.0001 0.73 (0.65;0.82), p < 0.0001
Vegetal extraction 1191 (0.8) 0.59 (0.48–0.73), p < 0.0001 0.70 (0.58;0.85), p < 0.0001
Mining 7046 (4.6) 0.81 (0.74–0.89), p < 0.0001 0.86 (0.79;0.93), p < 0.0001
Tourism 3182 (2.1) 0.79 (0.71–0.89), p < 0.0001 0.76 (0.68;0.84), p < 0.0001
Agriculture livestock 32,919 (21.7) 0.77 (0.73–0.82), p < 0.0001 0.79 (0.75;0.83), p < 0.0001
Others 89,132 (58.7) 0.85 (0.81–0.9), p < 0.0001 0.91 (0.87;0.95), p < 0.0001
Domestic 14,741 (9.7) REF REF
Years in school Complete graduation 1341 (0.9) 1.14 (0.97–1.35), p = 0.12 1.04 (0.89;1.22), p = 0.63
Complete high school 13,647 (9) 1.14 (1.06–1.23), p < 0.0001 1.07 (1.00;1.15), p = 0.04
Incomplete high school 12,070 (8) 1.15 (1.07–1.24), p < 0.0001 1.09 (1.02;1.17), p = 0.02
Complete fundamental studies 9745 (6.4) 1.11 (1.03–1.2), p = 0.01 1.05 (0.97;1.13), p = 0.24
Not informed 17,596 (11.6) 1.33 (1.22–1.44), p < 0.0001 1.27 (1.17;1.37), p < 0.0001
Incomplete fundamental studies 81,190 (53.5) 1.12 (1.06–1.18), p < 0.0001 1.06 (1.01;1.12), p = 0.02
Illiterate 16,195 (10.7) REF REF
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suggestions from others in the literature [24]. It is not 
clear if this is a function of a long duration of post-treat-
ment prophylactic effect of ACT to suppress P. falcipa-
rum infections.
It was found that the time to recurrence appears to 
reduce with each subsequent episode of vivax recurrence. 
Although these observations are in contrast with the 
current understanding of hypnozoite activation which 
implies a gradual lengthening, rather than shortening 
with each successive relapse, these results are consistent 
with previous observations in Brazil [25]. The underlying 
assumption related to the gradual lengthening hypoth-
esis is that with multiclonal infections the earliest active 
and more rapidly multiplying parasite became patent first 
[24]. These observations relied on artificial infection and 
animal models. Although this study cannot differenti-
ate with relapse, reinfections and recrudescence, it does 
not provide strong support for a gradual lengthening of 
relapse intervals. Further research to address the issue is 
needed.
The observation that the addition of primaquine was 
already effective in preventing recurrence in the first 
28 days is interesting. It implies that the addition of pri-
maquine to chloroquine either reduced recrudescence 
or early relapses and may support the synergic effect of 
primaquine and chloroquine in the blood stage [26–29]. 
This trend is also seen in the following period until the 
60th day. A small (RR = 1.14) effect was also seen beyond 
60  days, but it is not clear if this reflects a long-lasting 
anti-relapse effect of primaquine [4] or a higher exposure 
risk in the non-primaquine recipients resulting in more 
new infections and thus a higher rate of recurrence.
The study design is an important limitation. This is a 
1-year retrospective open cohort, meaning that patients 
infected before the study start yet recurring during the 
study were considered as initial events. Second, the only 
way that the effectiveness of short course of primaquine 
could be evaluated was to use the pregnant popula-
tion as the reference group because this group does not 
receive primaquine during pregnancy. However, this is 
a biased population and the results must be interpreted 
with this in mind. Potential confounders include changes 
in mosquito biting frequency during pregnancy, altered 
personal protection and healthcare-seeking behaviour, 
altered immunological responses, and changes in dis-
tribution of drugs, although chloroquine pharmacoki-
netics parameters in pregnant women does not appear 
to be very different from the rest of the population [30]. 
Despite these limitations, our results do suggest that the 
current national treatment guidelines in Brazil are effec-
tive in reducing relapse.
Additionally, every data matching strategy has its 
limitations and they can result in different number of 
recurrences depending on the reliability of the data entry. 
A unique identifier for the patients would allow a better 
evaluation of the sensitivity and specificity of the strategy 
and increase the use of the database as routine. Besides 
the data quality concerns, microscopy does not allow 
differentiation between relapse, recrudescence and rein-
fection of the P. vivax episodes and the aggregate recur-
rence was used in the analysis. Routine genotyping to 
differentiate these is currently not feasible at scale under 
programmatic conditions. Efforts to differentiate relapse 
and reinfection in this study by restringing the analysis to 
infants born during the study and, therefore, free of hyp-
nozoites, was not successful as the sample of newborns 
was too small. Multi-year cohorts may address this issue.
Conclusions
Overall, this study confirmed that under real-life condi-
tions, short-course primaquine was equally as effective as 
the 14-day regimen, which is the standard in many other 
countries. ACT-primaquine combinations were also 
more effective than chloroquine alone or chloroquine-
primaquine combinations in delaying recurrence. The 
concomitant use of primaquine and chloroquine either 
reduced recrudescence or very early relapse and may 
support their synergic effect in the blood stage. Finally, 
the study demonstrates the feasibility of using record 
linkage to identify potential P. vivax recurrences, associ-
ated risk factors and impact of treatment using routine 
surveillance data. These routine data could also poten-
tially provide a baseline for evaluation of further malaria 
control interventions that address the malaria control in 
Brazil.
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